Seizure Disorders

Latest News

Epilepsy Therapy Cenobamate Designated Schedule V Controlled Substance

The DEA has designated Xcopri (cenobamate; SK Life Science) as a schedule V controlled substance, indicating a lower potential for abuse.

FDA Approves MRI Labeling for Neurostimulation System Designed to Prevent Seizures

The RNS System consists of a small neurostimulator that is surgically implanted into the skull, delivering an electrical stimulation to the brain via leads when abnormal activity is detected.

Hepatic Exacerbation and Risk for Hospitalization for Epilepsy, Status Epilepticus

In patients with a known diagnosis of cirrhosis, hepatic exacerbations may increase the risk for hospitalization for epilepsy and status epilepticus.

Self-Monitoring More Effective Than Cognitive Behavioral Therapy for Insomnia in Epilepsy

Self-monitoring behaviors may serve as a potential mediator of therapeutic change for patients with epilepsy.

Phenytoin Oral Suspension Recalled Due to Potential for Inaccurate Dosing

Taro Pharmaceuticals announced the voluntary recall of 2 lots of Phenytoin Oral Suspension 125mg/mL packaged in 237mL bottles that may not resuspend properly when shaken, which can potentially result in under or overdosing.

FDA Accepts NDA for Diazepam Buccal Film for Management of Seizure Clusters

The Food and Drug Administration (FDA) has accepted for review the New Drug Application for Libervant® (diazepam; Aquestive Therapeutics) buccal film for the management of seizure clusters.

Supplemental NDA Submitted for Epidiolex for Tuberous Sclerosis Complex

Epidiolex is currently approved in the US to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

Road Proximity Linked to Incidence of Neurologic Diseases

Road proximity is associated with an increased incidence of specific neurologic disorders.

Vigabatrin Approved for Younger Patients With Complex Partial Seizures

The FDA has expanded the approval of vigabatrin to include treatment of refractory complex partial seizures in patients aged 2 to <10 years of age.

Diazepam Nasal Spray Approved for Seizure Clusters

The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.